Say No To Trading
Public Markets Investor, Opportunistic Buying & Cost-Basis Management
Rollins and Rentokil are pest-control roll-ups built on cheap money, which let them pay acquisition multiples that only made sense thanks to Rollins' premium valuation. Unlike aerospace aftermarket parts makers or specialty MEP contractors, pest control is commoditized: treating a house or a larger building uses a similar process, which means more competition and less profit. David Royce founded and sold four pest-control companies, often to Terminix, now part of Rentokil. x.comÂ
Rollins still looks expensive for a pest control company at about 29x earnings and 26x forward, even after falling from a stupidly expensive 65x. @DudeWhoInvests notes the stock is down nearly 50% this year while fundamentals kept rising. x.comÂ
Rentokil Initial looks very troubled because Terminix has been a problem asset forever, and pest control is ultimately a people business that is hard to turn around overnight. That does not mean it can't work. x.comÂ
Rollins' mission-critical, recurring pest control business has grown revenue for 25 consecutive years, through every crisis. About 80% of revenue is recurring, and nobody cancels pest control with termites or rodents in the house. Revenue grew 10% a year in the financial crisis and 12% in 2020, and adjusted EBITDA margins have risen to 23%. With 13% of a fragmented US market, it keeps taking share through acquisitions, operating leverage and pricing power. The catch: the stock isn't cheap. x.comÂ
Ongoing LLM pressure on lead generation and private-equity competition make Rollins look expensive. Guidance was cut for a second straight quarter, with implied fourth-quarter residential growth potentially negative. A price closer to $25 looks like an opportunity to scale back into a short. x.comÂ
Rollins' slowing organic growth puts both its earnings expectations and premium multiple at risk. Guidance fell from 7-8% to 4-6%, the quarter delivered 4.4%, and growth was 8.5% two years ago. A still-growing business can be repriced when earnings miss the model and investors pay less for each dollar earned. x.comÂ
Rentokil remains cheap, though cheapness is not a thesis after organic growth decelerated and it pulled its 2027 margin target to reinvest. It trades at 16x 2026 and 14.5x 2027 earnings, organic growth should likely improve on the back of that reinvestment, and the commercial focus is good. The quarter was worse for Rollins than for Rentokil. x.comÂ
Rollins is spending more just to stand still, so a ~50% drop does not make it cheap. With ~15-20% blended churn, 5% growth needs about 20% new customers, three in four just refilling the base. Sales and marketing per $1 of organic revenue added rose from $2.07 in FY25 to $2.37 in H1 2026, effectively maintenance capex. Q2 cut organic growth guidance to at least 6% and incremental margin to at least 10% versus a 30%+ target. AI search, an FTC non-compete ban and staff turnover add headwinds. … Show more
Rollins has fallen far faster than seemed believable. x.comÂ
Rollins, owner of Orkin, is a solid buy because its route-based pest-control model, with recurring revenue, strong retention, pricing power and low capital needs, lets it keep consolidating a fragmented industry while weaker competitors struggle. Leverage is just 1x, revenue grew 7.9% with organic growth above 6%, and consensus sees 12% growth in 2027 and 11% in 2028. Shares trade near $36 versus $42 of intrinsic value. x.comÂ
Rollins is a great business, but 30x earnings for low double-digit growth is not compelling. @DimitryNakhla notes the stock has gone nowhere in six years even as earnings doubled, a warning against overpaying for a mid-teens grower. x.comÂ
